Klink, M.; Rahman, M.A.; Song, C.; Dhanyamraju, P.K.; Ehudin, M.; Ding, Y.; Steffens, S.; Bhadauria, P.; Iyer, S.; Aliaga, C.;
et al. Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. Cancers 2021, 13, 1127.
https://doi.org/10.3390/cancers13051127
AMA Style
Klink M, Rahman MA, Song C, Dhanyamraju PK, Ehudin M, Ding Y, Steffens S, Bhadauria P, Iyer S, Aliaga C,
et al. Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. Cancers. 2021; 13(5):1127.
https://doi.org/10.3390/cancers13051127
Chicago/Turabian Style
Klink, Morgann, Mohammad Atiqur Rahman, Chunhua Song, Pavan Kumar Dhanyamraju, Melanie Ehudin, Yali Ding, Sadie Steffens, Preeti Bhadauria, Soumya Iyer, Cesar Aliaga,
and et al. 2021. "Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia" Cancers 13, no. 5: 1127.
https://doi.org/10.3390/cancers13051127
APA Style
Klink, M., Rahman, M. A., Song, C., Dhanyamraju, P. K., Ehudin, M., Ding, Y., Steffens, S., Bhadauria, P., Iyer, S., Aliaga, C., Desai, D., Huang, S., Claxton, D., Sharma, A., & Gowda, C.
(2021). Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. Cancers, 13(5), 1127.
https://doi.org/10.3390/cancers13051127